Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Feb 19, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging technique called Al18F-NOTA-FAPI PET/CT to help identify and better understand certain types of cancer, specifically those that express a protein called fibroblast-activated protein. The goal is to see how effective this imaging method is in detecting malignant tumors, which are cancers that can spread and cause serious health problems. The study is currently looking for participants who are between the ages of 65 and 74 and have either suspected or clearly diagnosed cancers that show these specific proteins.

To be eligible for this trial, participants must be willing to provide written consent and agree to follow the study's procedures. However, those who are pregnant, breastfeeding, or have other medical conditions that could affect their ability to participate will not be included. If you choose to join, you can expect to undergo a whole-body PET/CT scan, which is a special type of imaging test that helps doctors see inside the body and understand how the cancer is behaving. This study aims to gather important information that could improve cancer diagnosis and treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with suspected or clearly diagnosed Malignant Tumors Expressing Fibroblast-activated Proteins
• • signed written consent.
• • Willing and able to cooperate with all projects in this study.
• Exclusion Criteria:
• • pregnancy;
• • breastfeeding;
• • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.